downloadDownload

Prospective observational study to investigate the added value of the health related quality of life and patient reported symptoms in the identification of the recommended phase II dose (RPIID) in phase I trials of molecularly targeted therapies.

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-5535 Call for proposal: PHRC12

Funded under: PHRC

Prospective observational study to investigate the added value of the health related quality of life and patient reported symptoms in the identification of the recommended phase II dose (RPIID) in phase I trials of molecularly targeted therapies.

- Summary
- DMPs

Partners

Institut Gustave Roussy , Centre Georges-François Leclerc , Institut Claudius Regaud , Institut Curie

Data Management Plans

Start a new DMP in Argos

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::7a69ae0c179168d9ab88a787ff12f90c&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Prospective observational study to investigate the added value of the health related quality of life and patient reported symptoms in the identification of the recommended phase II dose (RPIID) in phase I trials of molecularly targeted therapies.

Prospective observational study to investigate the added value of the health related quality of life and patient reported symptoms in the identification of the recommended phase II dose (RPIID) in phase I trials of molecularly targeted therapies.

Loading